Tuesday, 13 October 2026European Markets

PGS Stock Over 9% Down So Far Today

Loading stream...

(VIANEWS) - Shares of PGS (Oslo Børs Benchmark Index_GI: PGS.OL) fell 9.31% to kr8.75 at 11:37 EST on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is sliding 0.01% to kr1,215.52, after two successive sessions in a row of gains. This seems, up until now, a somewhat down trend trading session today.

PGS's last close was kr9.65, 26.62% under its 52-week high of kr13.15.

About PGS

PGS ASA, together with its subsidiaries, operates as a marine geophysical company primarily in Norway. The company provides a range of seismic and reservoir services, including data acquisition, imaging, interpretation, and field evaluation to oil and gas companies, as well as carbon storage and offshore wind markets. It also operates in the Asia Pacific, Canada, Egypt, the Americas, Angola, the United Kingdom, Greece, Cyprus, Ukraine, Brazil, South Africa, other African countries, the Middle East, and internationally. The company was formerly known as Petroleum Geo-Services ASA and changed its name to PGS ASA in May 2019. PGS ASA was founded in 1991 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PGS has a trailing twelve months EPS of kr-0.63.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -8.68%.

Sales Growth

PGS's sales growth is 49.3% for the present quarter and negative 22.7% for the next.

More news about PGS (PGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com